---
document_datetime: 2025-12-02 04:50:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pylclari.html
document_name: pylclari.html
version: success
processing_time: 0.1050887
conversion_datetime: 2025-12-27 09:19:24.271339
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pylclari

[RSS](/en/individual-human-medicine.xml/67693)

##### Authorised

This medicine is authorised for use in the European Union

piflufolastat (18F) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pylclari](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pylclari is a diagnostic medicine used in adults with prostate cancer to detect prostate cancer cells with a protein called prostate-specific membrane antigen (PSMA), using the body scan known as positron-emission tomography (PET).

It is used:

- to find out whether prostate cancer has spread to lymph nodes and other tissues outside the prostate before treatment is started;
- to find out whether prostate cancer has returned in patients whose blood levels of prostate specific antigen (PSA) are increasing after previous treatment.

Pylclari contains the active substance piflufolastat ( 18 F).

Expand section

Collapse section

## How is Pylclari used?

The medicine can only be given in a designated nuclear medicine facility by trained healthcare professionals with technical expertise in using and handling nuclear medicine imaging agents.

Pylclari is given as an injection into a vein and a PET scan is done after the injection.

For more information about using Pylclari, see the package leaflet or contact your doctor or pharmacist.

## How does Pylclari work?

The active substance of Pylclari, piflufolastat ( 18 F), binds to PSMA, which is found in large numbers on the surface of most prostate cancer cells. When this diagnostic medicine is given to a patient, it binds to PSMA and is taken up by the cells. Because it contains radioactive fluorine ( 18 F) it gives off radiation, which can be detected during a PET scan. Doctors can then see where in the body the cancer cells are. Pylclari does not treat prostate cancer.

## What benefits of Pylclari have been shown in studies?

The benefits of Pylclari were shown in three main studies.

In the first study in 385 men with prostate cancer, all patients received Pylclari and underwent a PET scan to check the location of cancer cells. After three different doctors had looked at the scan, patients with high-risk cancer then had surgery to remove their prostate. Among the 252 patients whose prostate was removed, the results of the PET scan correctly showed the absence of cancer cells in parts of their prostate in over 96% of patients.

The second study included 208 men with suspected prostate cancer that had come back after treatment and that could not be confirmed using a standard scan. In this study, all patients received Pylclari and underwent a PET scan. The results of the PET scan showed at least one cancer lesion in 59 to 66% of patients, depending on the doctor analysing the results of the scan, and the scan correctly identified the location of the lesion in 85 to 87% of them.

The third study included 215 men with suspected prostate cancer that had returned after treatment. These patients received either Pylclari or 18 F-fluorocholine (another diagnostic medicine used for imaging) before they had a PET scan, and then received the other diagnostic medicine and had another PET scan up to 12 days later. The PET scans revealed prostate cancer in 58% of these patients after they were given Pylclari, compared with 40% after patients had received the other diagnostic medicine.

## What are the risks associated with Pylclari?

For the full list of side effects and restrictions with Pylclari, see the package leaflet.

The most common side effects with Pylclari (which may affect more than 1 in 100 people) include headache and loss of taste (dysgeusia).

## Why is Pylclari authorised in the EU?

The European Medicines Agency considered that the use of Pylclari offered improvements over existing methods for detecting prostate cancer that has not yet been treated or has returned, and for screening patients who may benefit from PSMA-targeted treatment. Pylclari's side effects were usually mild and its safety profile was considered acceptable. The Agency therefore decided that Pylclari's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pylclari?

The company that markets Pylclari will provide medical practitioners who are expected to use this diagnostic medicine with educational materials to support interpretation of PET scans.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pylclari have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pylclari are continuously monitored. Suspected side effects reported with Pylclari are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pylclari

Pylclari received a marketing authorisation valid throughout the EU on 24 July 2023.

Pylclari : EPAR - Medicine overview

Reference Number: EMA/245956/2023

English (EN) (144.96 KB - PDF)

**First published:** 28/07/2023

[View](/en/documents/overview/pylclari-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-671)

български (BG) (170.97 KB - PDF)

**First published:**

28/07/2023

[View](/bg/documents/overview/pylclari-epar-medicine-overview_bg.pdf)

español (ES) (145.16 KB - PDF)

**First published:**

28/07/2023

[View](/es/documents/overview/pylclari-epar-medicine-overview_es.pdf)

čeština (CS) (166.69 KB - PDF)

**First published:**

28/07/2023

[View](/cs/documents/overview/pylclari-epar-medicine-overview_cs.pdf)

dansk (DA) (143.53 KB - PDF)

**First published:**

28/07/2023

[View](/da/documents/overview/pylclari-epar-medicine-overview_da.pdf)

Deutsch (DE) (148.66 KB - PDF)

**First published:**

28/07/2023

[View](/de/documents/overview/pylclari-epar-medicine-overview_de.pdf)

eesti keel (ET) (140.53 KB - PDF)

**First published:**

28/07/2023

[View](/et/documents/overview/pylclari-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.81 KB - PDF)

**First published:**

28/07/2023

[View](/el/documents/overview/pylclari-epar-medicine-overview_el.pdf)

français (FR) (144.23 KB - PDF)

**First published:**

28/07/2023

[View](/fr/documents/overview/pylclari-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.66 KB - PDF)

**First published:**

28/07/2023

[View](/hr/documents/overview/pylclari-epar-medicine-overview_hr.pdf)

italiano (IT) (144.58 KB - PDF)

**First published:**

28/07/2023

[View](/it/documents/overview/pylclari-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (175.36 KB - PDF)

**First published:**

28/07/2023

[View](/lv/documents/overview/pylclari-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (164.84 KB - PDF)

**First published:**

28/07/2023

[View](/lt/documents/overview/pylclari-epar-medicine-overview_lt.pdf)

magyar (HU) (165.02 KB - PDF)

**First published:**

28/07/2023

[View](/hu/documents/overview/pylclari-epar-medicine-overview_hu.pdf)

Malti (MT) (168.52 KB - PDF)

**First published:**

28/07/2023

[View](/mt/documents/overview/pylclari-epar-medicine-overview_mt.pdf)

Nederlands (NL) (145.04 KB - PDF)

**First published:**

28/07/2023

[View](/nl/documents/overview/pylclari-epar-medicine-overview_nl.pdf)

polski (PL) (172.87 KB - PDF)

**First published:**

28/07/2023

[View](/pl/documents/overview/pylclari-epar-medicine-overview_pl.pdf)

português (PT) (136.24 KB - PDF)

**First published:**

28/07/2023

[View](/pt/documents/overview/pylclari-epar-medicine-overview_pt.pdf)

română (RO) (164.54 KB - PDF)

**First published:**

28/07/2023

[View](/ro/documents/overview/pylclari-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.88 KB - PDF)

**First published:**

28/07/2023

[View](/sk/documents/overview/pylclari-epar-medicine-overview_sk.pdf)

slovenščina (SL) (164.39 KB - PDF)

**First published:**

28/07/2023

[View](/sl/documents/overview/pylclari-epar-medicine-overview_sl.pdf)

Suomi (FI) (140.88 KB - PDF)

**First published:**

28/07/2023

[View](/fi/documents/overview/pylclari-epar-medicine-overview_fi.pdf)

svenska (SV) (143.78 KB - PDF)

**First published:**

28/07/2023

[View](/sv/documents/overview/pylclari-epar-medicine-overview_sv.pdf)

Pylclari : EPAR - Risk-management-plan summary

English (EN) (517.2 KB - PDF)

**First published:** 28/07/2023

[View](/en/documents/rmp-summary/pylclari-epar-risk-management-plan-summary_en.pdf)

## Product information

Pylclari : EPAR - Product information

English (EN) (470.5 KB - PDF)

**First published:** 28/07/2023

**Last updated:** 05/11/2025

[View](/en/documents/product-information/pylclari-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-625)

български (BG) (548.32 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/pylclari-epar-product-information_bg.pdf)

español (ES) (464.14 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

22/07/2025

[View](/es/documents/product-information/pylclari-epar-product-information_es.pdf)

čeština (CS) (500.76 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/pylclari-epar-product-information_cs.pdf)

dansk (DA) (515.53 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/da/documents/product-information/pylclari-epar-product-information_da.pdf)

Deutsch (DE) (485.75 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/de/documents/product-information/pylclari-epar-product-information_de.pdf)

eesti keel (ET) (469.36 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/et/documents/product-information/pylclari-epar-product-information_et.pdf)

ελληνικά (EL) (539.42 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/el/documents/product-information/pylclari-epar-product-information_el.pdf)

français (FR) (477.11 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/pylclari-epar-product-information_fr.pdf)

hrvatski (HR) (578.57 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/pylclari-epar-product-information_hr.pdf)

íslenska (IS) (488.74 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/is/documents/product-information/pylclari-epar-product-information_is.pdf)

italiano (IT) (472.83 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/it/documents/product-information/pylclari-epar-product-information_it.pdf)

latviešu valoda (LV) (502.06 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/pylclari-epar-product-information_lv.pdf)

lietuvių kalba (LT) (502.22 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/pylclari-epar-product-information_lt.pdf)

magyar (HU) (478.29 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/pylclari-epar-product-information_hu.pdf)

Malti (MT) (533.7 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/pylclari-epar-product-information_mt.pdf)

Nederlands (NL) (467.03 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/pylclari-epar-product-information_nl.pdf)

norsk (NO) (466.28 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/no/documents/product-information/pylclari-epar-product-information_no.pdf)

polski (PL) (474.64 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/pylclari-epar-product-information_pl.pdf)

português (PT) (467.54 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/pylclari-epar-product-information_pt.pdf)

română (RO) (513.24 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/pylclari-epar-product-information_ro.pdf)

slovenčina (SK) (471.84 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/pylclari-epar-product-information_sk.pdf)

slovenščina (SL) (522.56 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/pylclari-epar-product-information_sl.pdf)

Suomi (FI) (466.91 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/pylclari-epar-product-information_fi.pdf)

svenska (SV) (459.17 KB - PDF)

**First published:**

28/07/2023

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/pylclari-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000304179 05/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pylclari : EPAR - All authorised presentations

English (EN) (112.08 KB - PDF)

**First published:** 28/07/2023

[View](/en/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-512)

български (BG) (108.82 KB - PDF)

**First published:**

28/07/2023

[View](/bg/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_bg.pdf)

español (ES) (67.72 KB - PDF)

**First published:**

28/07/2023

[View](/es/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_es.pdf)

čeština (CS) (101.15 KB - PDF)

**First published:**

28/07/2023

[View](/cs/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (88.16 KB - PDF)

**First published:**

28/07/2023

[View](/da/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (88.35 KB - PDF)

**First published:**

28/07/2023

[View](/de/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (65.48 KB - PDF)

**First published:**

28/07/2023

[View](/et/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (79.98 KB - PDF)

**First published:**

28/07/2023

[View](/el/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_el.pdf)

français (FR) (59.41 KB - PDF)

**First published:**

28/07/2023

[View](/fr/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (77.81 KB - PDF)

**First published:**

28/07/2023

[View](/hr/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (62.86 KB - PDF)

**First published:**

28/07/2023

[View](/is/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.52 KB - PDF)

**First published:**

28/07/2023

[View](/it/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.38 KB - PDF)

**First published:**

28/07/2023

[View](/lv/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (58.74 KB - PDF)

**First published:**

28/07/2023

[View](/lt/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.45 KB - PDF)

**First published:**

28/07/2023

[View](/hu/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (59.52 KB - PDF)

**First published:**

28/07/2023

[View](/mt/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.86 KB - PDF)

**First published:**

28/07/2023

[View](/nl/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.79 KB - PDF)

**First published:**

28/07/2023

[View](/no/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_no.pdf)

polski (PL) (80.39 KB - PDF)

**First published:**

28/07/2023

[View](/pl/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.45 KB - PDF)

**First published:**

28/07/2023

[View](/pt/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_pt.pdf)

română (RO) (76.04 KB - PDF)

**First published:**

28/07/2023

[View](/ro/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.68 KB - PDF)

**First published:**

28/07/2023

[View](/sk/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.06 KB - PDF)

**First published:**

28/07/2023

[View](/sl/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.92 KB - PDF)

**First published:**

28/07/2023

[View](/fi/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.93 KB - PDF)

**First published:**

28/07/2023

[View](/sv/documents/all-authorised-presentations/pylclari-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pylclari Active substance Piflufolastat (18F) International non-proprietary name (INN) or common name piflufolastat (18F) Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code V09

### Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

### Therapeutic indication

This medicinal product is for diagnostic use only.

Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

- Primary staging of patients with high-risk PCa prior to initial curative therapy,
- To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.

Pylclari is indicated for use with positron emission tomography (PET).

## Authorisation details

EMA product number EMEA/H/C/005520

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Curium Pet France

Biopole Clermont Limagne

Opinion adopted 25/05/2023 Marketing authorisation issued 27/11/2023 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pylclari : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (218.89 KB - PDF)

**First published:** 26/05/2025

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/pylclari-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pylclari : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (126.85 KB - PDF)

**First published:** 30/11/2023

**Last updated:** 26/05/2025

[View](/en/documents/procedural-steps-after/pylclari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Pylclari : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/279917/2023

English (EN) (3.16 MB - PDF)

**First published:** 28/07/2023

[View](/en/documents/assessment-report/pylclari-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pylclari

Adopted

Reference Number: EMA/CHMP/235199/2023

English (EN) (154.46 KB - PDF)

**First published:** 26/05/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pylclari_en.pdf)

#### News on Pylclari

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-may-2023) 26/05/2023

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)